Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenytoin
Drug ID BADD_D01765
Description Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market.[A189219]
Indications and Usage Phenytoin is indicated to treat grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery.[L9362] Injectable phenytoin and [Fosphenytoin], which is the phosphate ester prodrug formulation of phenytoin[A188571], are indicated to treat tonic-clonic status epilepticus, and for the prevention and treatment of seizures occurring during neurosurgery.[L10740]
Marketing Status approved; vet_approved
ATC Code N03AB02
DrugBank ID DB00252
KEGG ID D00512
MeSH ID D010672
PubChem ID 1775
TTD Drug ID D0E4DW
NDC Product Code 51552-0553; 66064-1030; 60687-275; 0615-8424; 51927-0300; 51927-1216; 52119-007; 51672-4069; 60687-156; 66689-036; 70518-1967; 12711-4444; 70518-0841; 66993-372; 0615-8260; 62991-1691; 17856-4070; 0121-0892; 51672-4146; 66689-775; 0009-0488; 59762-0531; 0904-7199; 49452-5340; 0071-2214; 17349-0007; 0071-0007; 0904-7079; 59762-5210
UNII 6158TKW0C5
Synonyms Phenytoin | Fenitoin | Diphenylhydantoin | 5,5-diphenylimidazolidine-2,4-dione | 5,5-Diphenylhydantoin | Difenin | Dihydan | Phenhydan | Epamin | Epanutin | Hydantol | Phenytoin Sodium | Sodium Diphenylhydantoinate | Diphenylhydantoinate, Sodium | Antisacer | Dilantin
Chemical Information
Molecular Formula C15H12N2O2
CAS Registry Number 57-41-0
SMILES C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Herbal interaction08.06.03.0050.000191%Not Available
Hyporesponsive to stimuli17.02.05.057--Not Available
Disorganised speech19.19.02.005; 17.02.08.0170.000191%Not Available
Administration site extravasation12.07.04.019; 08.02.04.0190.000421%Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000191%Not Available
Central hypothyroidism14.11.01.049; 05.02.03.0090.000191%Not Available
Cerebellar cognitive affective syndrome19.21.02.013; 17.02.02.0170.000382%Not Available
Decorticate posture17.02.05.067; 15.03.05.0090.000191%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000765%Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000191%Not Available
Hoffmann's sign17.02.01.0090.000191%Not Available
Hypersensitivity myocarditis10.01.03.055; 02.04.03.0060.000191%Not Available
Hypersensitivity pneumonitis22.01.01.027; 10.01.03.0560.000191%Not Available
Idiopathic intracranial hypertension17.07.02.0110.000765%Not Available
Illness08.01.03.0910.001224%Not Available
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.000191%Not Available
Periorbital swelling10.01.05.025; 06.08.03.032; 23.04.01.0250.000191%Not Available
Pleomorphic adenoma16.05.04.005; 07.20.02.0060.000191%Not Available
Reaction to excipient10.01.01.0420.000612%Not Available
Severe cutaneous adverse reaction23.03.05.011; 12.03.01.070; 11.07.01.031; 10.01.01.0440.000191%Not Available
SJS-TEN overlap23.03.01.041; 12.03.01.069; 11.07.01.030; 10.01.01.0430.000287%Not Available
Therapeutic product effect incomplete08.06.01.0520.003040%Not Available
Therapeutic response changed08.06.01.0590.000899%Not Available
Urticaria papular23.04.02.019; 10.01.06.0190.000382%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 20th Page    First    Pre   20    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene